JP Morgan Chase
FATE icon

JP Morgan Chase’s Fate Therapeutics FATE Stock Holding History

JP Morgan Chase’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-132,000
Closed -$2.93M – 5468
2020
Q1 		$2.93M Buy
132,000
+57,000
+76% +$1.44M ﹤0.01% 2684
2019
Q4 		$1.47M Buy
+75,000
New +$1.19M ﹤0.01% 3607

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

JP Morgan Chase's FATE Position: Q2 2026 in Review

JP Morgan Chase reduced its Fate Therapeutics (FATE) stake by 80% in Q2 2026, selling an estimated $66.4K and leaving 8,996 shares worth $21.8K. The position accounts for ﹤0.01% of the portfolio, ranked #6709.

JP Morgan Chase first reported a position in FATE in Q3 2016 and has held it in 39 quarters since. The position peaked at $136M in Q2 2021. 156 funds tracked by Wall St. Rank hold FATE as of Q2 2026.

  • JP Morgan Chase held 8,996 shares of Fate Therapeutics worth $21.8K as of Q2 2026.
  • JP Morgan Chase sold 35,892 Fate Therapeutics shares in Q2 2026, an estimated $66.4K.
  • Fate Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #6709 holding.
  • JP Morgan Chase first reported a position in Fate Therapeutics in Q3 2016 and has held it in 39 quarters since.
  • JP Morgan Chase's Fate Therapeutics position peaked at $136M in Q2 2021.
  • 156 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.